LeMaitre Vascular (NASDAQ:LMAT) Shares Cross Above 200 Day Moving Average – Time to Sell?

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $96.01 and traded as high as $97.83. LeMaitre Vascular shares last traded at $92.34, with a volume of 284,066 shares traded.

Analyst Ratings Changes

Several equities research analysts have recently commented on LMAT shares. Weiss Ratings raised shares of LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 20th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Citizens Jmp raised their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company raised their target price on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average target price of $112.60.

LeMaitre Vascular Stock Performance

The company has a market capitalization of $2.11 billion, a PE ratio of 34.07, a PEG ratio of 2.68 and a beta of 0.54. The business’s 50-day moving average is $104.76 and its 200-day moving average is $96.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same period last year, the company posted $0.48 EPS. LeMaitre Vascular’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

Insider Activity at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares of the company’s stock, valued at $401,143. This trade represents a 43.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 54,453 shares of company stock valued at $5,906,174 in the last three months. Company insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of LMAT. Glenmede Trust Co. NA increased its stake in LeMaitre Vascular by 14.8% during the 1st quarter. Glenmede Trust Co. NA now owns 9,547 shares of the medical instruments supplier’s stock valued at $1,042,000 after purchasing an additional 1,234 shares in the last quarter. Bank of America Corp DE increased its stake in LeMaitre Vascular by 39.0% during the 1st quarter. Bank of America Corp DE now owns 180,095 shares of the medical instruments supplier’s stock valued at $19,661,000 after purchasing an additional 50,497 shares in the last quarter. Janus Henderson Group PLC increased its stake in LeMaitre Vascular by 28.8% during the 1st quarter. Janus Henderson Group PLC now owns 10,832 shares of the medical instruments supplier’s stock valued at $1,183,000 after purchasing an additional 2,422 shares in the last quarter. Smith Group Asset Management LLC increased its stake in LeMaitre Vascular by 69.0% during the 1st quarter. Smith Group Asset Management LLC now owns 6,985 shares of the medical instruments supplier’s stock valued at $763,000 after purchasing an additional 2,851 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in LeMaitre Vascular by 28.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier’s stock valued at $152,000 after purchasing an additional 308 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.